Top 5 Growth Opportunities for the Pharmaceutical Industry, 2024

Top 5 Growth Opportunities for the Pharmaceutical Industry, 2024

Tech-enabled Partnerships Propelling Drug Discovery and Development in Precision Oncology, Rare Diseases, and Obesity

RELEASE DATE
03-Jan-2024
REGION
Global
Research Code: PFC6-01-00-00-00
SKU: HC_2023_491
AvailableYesPDF Download
$2,450.00
In stock
SKU
HC_2023_491
$2,450.00
ENQUIRE NOW

Description

In 2024, the life science (LS) industry’s focus on precision health will intensify. LS companies will augment their omics-based research capabilities and increasingly deploy AI and bioinformatics to discover personalized therapies. Partnerships between pharmaceutical companies and technology vendors will multiply, to support innovation in drug discovery for rare diseases, obesity, and oncology.

The possibility of targeting previously undruggable targets will drive investments and partnerships in ribonucleic acid (RNA) technology, protein degradation (PROTAC), and antibody engineering technologies. Precision oncology is a vital area of focus, reinforced by the establishment of more public-private partnerships. There will be an increase in cross-industry collaboration between pharmaceutical companies, contract research organizations (CROs), digital therapeutics, diagnostic companies, real-world evidence (RWE) solution vendors, next-generation sequencing (NGS) companies, and medical device players. The implementation of artificial intelligence will intensify for accelerated drug discovery and drug repurposing, clinical trial democratization and design, RWD analysis, manufacturing automation, and supply chain transparency, with resulting benefits extending to patients, healthcare providers, and the pharmaceutical industry overall.

Table of Contents

Strategic Imperatives

Top 5 Growth Opportunities

Growth Opportunity 1: AI-enabled Drug Repurposing for Rare Diseases

Growth Opportunity 2: PPPs for Precision Oncology Scaleup in Middle East and APAC

Growth Opportunity 3: Agile Partnership Model for Drug Discovery and Development

Growth Opportunity 4: Targeting Undruggable Proteins with Emerging Biotech Platforms

Growth Opportunity 5: Combination Therapies for Obesity Management

Next Steps

Legal Disclaimer

In 2024, the life science (LS) industry s focus on precision health will intensify. LS companies will augment their omics-based research capabilities and increasingly deploy AI and bioinformatics to discover personalized therapies. Partnerships between pharmaceutical companies and technology vendors will multiply, to support innovation in drug discovery for rare diseases, obesity, and oncology. The possibility of targeting previously undruggable targets will drive investments and partnerships in ribonucleic acid (RNA) technology, protein degradation (PROTAC), and antibody engineering technologies. Precision oncology is a vital area of focus, reinforced by the establishment of more public-private partnerships. There will be an increase in cross-industry collaboration between pharmaceutical companies, contract research organizations (CROs), digital therapeutics, diagnostic companies, real-world evidence (RWE) solution vendors, next-generation sequencing (NGS) companies, and medical device players. The implementation of artificial intelligence will intensify for accelerated drug discovery and drug repurposing, clinical trial democratization and design, RWD analysis, manufacturing automation, and supply chain transparency, with resulting benefits extending to patients, healthcare providers, and the pharmaceutical industry overall.
More Information
Author Supriya Lala Kundu
Industries Healthcare
No Index No
Is Prebook No
Podcast No
WIP Number PFC6-01-00-00-00